The FDA required labeling changes for the programmed cell death 1 inhibitor pembrolizumab and thalidomide-analogue immunomodulatory agents to include information on increased mortality in multiple myeloma. Yet PD-1 therapy’s role in the disease is not a closed book.
No takes yet. Share an insight, caveat, or question.
Gormley et al. (2018) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: